KPTI — Karyopharm Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $48.16m
- $200.33m
- $145.24m
Annual cashflow statement for Karyopharm Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -196 | -124 | -165 | -143 | -76.4 |
| Depreciation | |||||
| Non-Cash Items | 33.7 | 39.4 | 35.1 | 18.4 | -51.1 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.34 | -23.2 | -20 | 31.4 | -0.302 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -160 | -107 | -150 | -92.7 | -127 |
| Capital Expenditures | -0.145 | -0.212 | -0.118 | 0 | -0.142 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -53.5 | 142 | -104 | 7.94 | 95.6 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -53.7 | 142 | -104 | 7.94 | 95.5 |
| Financing Cash Flow Items | — | 60 | 0 | 0 | -2.59 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 172 | 73.6 | 194 | 1.12 | 41.6 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -41.6 | 108 | -60.6 | -83.7 | 9.62 |